Download Files:
CVN424
$310 – $2,400
Products Details
Product Description
– CVN424 is an orally active and selective GPR6 inverse agonist with a Ki of 9.4 nM and an EC50 of 38 nM. CVN424 is brain-penetrant and has the potential for Parkinson disease research[1][2].
Web ID
– HY-134661A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C24H29F2N5O3
References
– [1]Huikai Sun, et al. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. J Med Chem. 2021 Apr 16.|[2]Nicola L Brice, et al. Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416.
CAS Number
– 2254706-21-1
Molecular Weight
– 473.52
Compound Purity
– 99.76
SMILES
– FC1=C(OC2CCN(C3=NC4=C(N=C3N[C@H]5COCC5)CN(CC4)C(C)=O)CC2)C=CC(F)=C1
Clinical Information
– Phase 2
Research Area
– Neurological Disease
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– GPR6
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
